Gene

PTPRD

protein tyrosine phosphatase receptor type D

Explore in graph →CI-GENE-00022530HGNC:9668 ENSG00000153707 NCBI 5789 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (4)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–4 of 4 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
PTPRD Mutation1
JSI-124	Head and Neck Carcinoma	Predictive	D	Supports Sensitivity Response	3	accepted	EID807 In this preclinical study, loss-of-function of PTPRD was mainly caused by mutation in head and neck cancer, as identified in TCGA data. PTPRD mutated cell-lines were more sensitive to STAT3 inhibition… (full text at CIViC) PMID 26267899 · Peyser et al., 2015 · Open in CIViC	civic
PTPRD R995C1
IGF1R Monoclonal Antibody + TemsirolimusCombination	Ewing Sarcoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID10061 An analysis of 8 ewing sarcoma patients revealed PTPRD mutations in 3 cases (V253I/W775*, T781A, R995C). 2 of 3 cases showed complete response (RECIST criteria) to IGF1R mAb based therapies. The R995C…

Cohorts

Alteration frequency by cohort (200)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved200 cohort rows (showing 50, sorted by frequency) · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Pan-Cancer MSK-IMPACT MET Validation Cohort (MSK 2022) mixed_impact_subset_2022	unmapped	Ssm	6	69

Literature

Linked publications (2)

25 per page, newest first.

pubmedPublishedShowing 1–2 of 2 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Germline PTPRD mutations in Ewing sarcoma: biologic and clinical implications.
· Oncotarget · 2013 · PMID 23800680 · validated civic_curation pubmed
Loss-of-Function PTPRD Mutations Lead to Increased STAT3 Activation and Sensitivity to STAT3 Inhibition in Head and Neck Cancer.
· PLoS One · 2015 · PMID 26267899 · validated civic_curation pubmed